Metabolic Response by 18F-FDG PET/CT in Metastatic Malignant Struma Ovarii Treated With Targeted Therapies

ABSTRACTMalignant struma ovarii (MSO) is a rare malignant ovarian tumor, histologically identical to differentiated thyroid cancers. Given the rarity of this disease, there are no treatment guidelines, and the place of imaging for response assessment remains controversial. We report a metabolic resp...

Full description

Saved in:
Bibliographic Details
Published in:Clinical nuclear medicine 2021-01, Vol.46 (1), p.52-54
Main Authors: Seban, Romain-David, Bozec, Laurence, Nascimento-Leite, Camila, Champion, Laurence
Format: Article
Language:English
Subjects:
Aged
Female
Fluorodeoxyglucose F18
Humans
Iodine Radioisotopes - therapeutic use
Molecular Targeted Therapy
Neoplasm Metastasis
Ovarian Neoplasms - diagnostic imaging
Ovarian Neoplasms - metabolism
Ovarian Neoplasms - pathology
Ovarian Neoplasms - therapy
Positron Emission Tomography Computed Tomography
Struma Ovarii - diagnostic imaging
Struma Ovarii - metabolism
Struma Ovarii - pathology
Struma Ovarii - therapy
Treatment Outcome
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACTMalignant struma ovarii (MSO) is a rare malignant ovarian tumor, histologically identical to differentiated thyroid cancers. Given the rarity of this disease, there are no treatment guidelines, and the place of imaging for response assessment remains controversial. We report a metabolic response assessed by F-FDG PET/CT in a 71-year-old woman with radioiodine-refractory metastatic MSO treated by targeted therapies (first line with lenvatinib and second line with pazopanib). This case of exceptional response also highlights the usefulness of F-FDG PET/CT for therapeutic assessment of targeted drugs in such a rare clinical entity of malignant MSO.
ISSN:0363-9762
1536-0229
DOI:10.1097/RLU.0000000000003374